Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MYOC | Q99972 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11689190 | 0.87 | HSPB1 (0.79) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL2011179 | 0.87 | HSPB1 (0.79) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL134332 | 0.87 | HSPB1 (0.79) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL9183872 | 0.87 | HSPB1 (0.79) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL8934595 | 0.85 | HSPB1 (0.76) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL311582 | 0.81 | KMT2A (0.73) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3208134 | 0.81 | HSPB1 (0.70) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL28051442 | 0.81 | HSPB1 (0.70) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL27680824 | 0.80 | HSPB1 (0.54) | HSPB1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL10840704 | 0.80 | ALDH1A1 (0.54) | KMT2AMEN1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | claimed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | claimed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | claimed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | claimed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | claimed |
| CN-105130951-B | Chiral ND 322, ND 364 or the sulfoxide analogs of ND 364 and preparation method thereof | 山东大学 | 2018-01-12 | — | — | CN | claimed |
| CN-106631834-A | Method for preparing 2,2-bis[4-(4-aminophenoxy)phenyl] propane | 自贡中天胜新材料科技有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-20110294853-A1 | Bis Aromatic Compounds for Use in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2011-12-01 | — | — | US | claimed |
| WO-2010029300-A1 | BIS AROMATIC COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2010-03-18 | — | — | WO | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| EP-0403618-B2 | METHYL ESTERS OF ALDIMINO- OR KETIMINO-OXY-ORTHO-TOLYLACRYLIC ACID, MANUFACTURING PROCESS AND FUNGICIDES CONTAINING THEM | BAYER AG (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2004017966-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS IN THE TREATMENT OF CHRONIC AND ACUTE PAIN | IONIX PHARMACEUTICALS LIMITED (GB) | 2004-03-04 | — | — | WO | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| EP-1134214-A1 | PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | claimed |
| EP-0058373-A1 | Substituted aliphatic secondary amines and their salts, pharmaceutical compositions containing them and their use | CIBA-GEIGY AG (CH) | 1982-08-25 | — | — | EP | claimed |
| US-4161534-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | claimed |
| US-4064265-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1977-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | HSPB1 3186/4885KMT2A 3655/4885MEN1 1372/4885 |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | HSPB1 3904/4885KMT2A 2209/4885MEN1 361/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | HSPB1 3904/4885KMT2A 2209/4885MEN1 361/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | HSPB1 4096/4885KMT2A 2442/4885MEN1 379/4885 |
| US-20110294853-A1 | Bis Aromatic Compounds for Use in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | HSPB1 2347/4885KMT2A 3724/4885MEN1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.